HOME > Investors > Press Releases
2014-05-16
Disclosure of Clinical Trial Entry & Exit (Voluntary Disclosure)
2014-04-08
Interpretation of ACC.14 Abstract
2014-03-20
2014.03 Product development status
2014-02-24
Financial Performance in 2013
2014-02-17
US FDA Grants Orphan-Drug Designation for ‘VM202-ALS’ for Treatment of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)
11 12 13 14 15 16 17 18 19 20